Sanofi Portfolio Analysis: Top Healthcare Holdings as of June 30, 2026

As of June 30, 2026, pharmaceutical giant Sanofi's investment portfolio totals $246.6 million.

This comprehensive analysis focuses on the largest positions within their holdings, all of which are concentrated in the Healthcare sector, reflecting Sanofi's expertise and strategic interests in this vital industry.

Top Holding: Inhibrx Biosciences (INBX)

The most significant position held by Sanofi is in Inhibrx Biosciences, Inc., identified by its ticker symbol INBX. This stock represents a substantial 20.54% allocation within their portfolio, making it the single largest holding as of the reporting date.

Inhibrx Biosciences (INBX) is valued at approximately $109.7 million in Sanofi's investment strategy. The company operates in a cutting-edge area of biotechnology focused on developing novel therapeutics targeting specific biological pathways, likely aligning with long-term healthcare trends and potential high-growth opportunities.

Notably, the number of shares held remains unchanged from the previous period, indicating stability or confidence in this particular investment. Sanofi's continued focus on Inhibrx Biosciences underscores its commitment to innovative biotech advancements.

Significant Position: Novavax (NVAX)

Another major component of Sanofi's portfolio is Novavax, represented by the ticker symbol NVAX. This investment accounts for 12.14% of their total holdings, or roughly $64.8 million.

Novavax (NVAX) operates in the broader Healthcare sector, specifically within vaccines and biodefense. Its current portfolio allocation suggests that Sanofi sees value in its research, development pipeline, and market potential within this critical field.

The share count for Novavax has also remained constant at 688,048 shares since the last reporting period. This stability implies a consistent strategic interest from Sanofi in this company's direction and prospects.

Strategic Focus: AnaptysBio (ANAB)

The third largest holding by weight is AnaptysBio, with the ticker symbol ANAB. It holds a 10.39% allocation, equivalent to about $55.5 million in value.

AnaptysBio is engaged in developing antibody-based therapies for various diseases. This focus aligns with Sanofi's broader interest in advanced therapeutic approaches within the Healthcare sector, potentially leveraging synergies or market opportunities.

Sanofi maintains an unchanged share count of 821,917 shares in AnaptysBio. The consistent investment signals a long-term perspective on this company and its potential contributions to healthcare innovation.

Additional Holdings: Immuneering Corp (IMRX) and Q32 Bio Inc. (QTTB)

In addition to these major positions, Sanofi holds shares in Immuneering Corp, ticker IMRX, contributing 2.53% or $13.5 million to the portfolio.

Immuneering Corp (IMRX) is involved in discovering and developing novel therapeutics targeting immune system dysregulation, another area relevant to healthcare advancements. The share count remains steady at 2,708,559 shares.

The smallest position among the top holdings by weight is Q32 Bio Inc., symbol QTTB, representing just 0.58% or $3.1 million of Sanofi's portfolio. This company focuses on developing treatments for rare diseases and neurological conditions. The share count here too shows no change from prior periods at 244,083 shares.

Overall, the data indicates that Sanofi's portfolio is heavily weighted towards Healthcare companies. The stability in share counts suggests a deliberate and long-term investment strategy focused on these specific sectors and firms.